<!-- Generated by pkgdown: do not edit by hand -->
<!DOCTYPE html>
<html lang="en">
  <head>
  <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<title>Get a list of evidence items — getAllEvidenceItems • civicr</title>

<!-- jquery -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.3.1/jquery.min.js" integrity="sha256-FgpCb/KJQlLNfOu91ta32o/NMZxltwRo8QtmkMRdAu8=" crossorigin="anonymous"></script>
<!-- Bootstrap -->

<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha256-916EbMg70RQy9LHiGkXzG8hSg9EdNy97GazNG/aiY1w=" crossorigin="anonymous" />
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha256-U5ZEeKfGNOja007MMD3YBI0A3OSZOQbeG6z2f2Y0hu8=" crossorigin="anonymous"></script>

<!-- Font Awesome icons -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha256-eZrrJcwDc/3uDhsdt61sL2oOBY362qM3lon1gyExkL0=" crossorigin="anonymous" />

<!-- clipboard.js -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.4/clipboard.min.js" integrity="sha256-FiZwavyI2V6+EXO1U+xzLG3IKldpiTFf3153ea9zikQ=" crossorigin="anonymous"></script>

<!-- sticky kit -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/sticky-kit/1.1.3/sticky-kit.min.js" integrity="sha256-c4Rlo1ZozqTPE2RLuvbusY3+SU1pQaJC0TjuhygMipw=" crossorigin="anonymous"></script>

<!-- pkgdown -->
<link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script>



<meta property="og:title" content="Get a list of evidence items — getAllEvidenceItems" />

<meta property="og:description" content="Retrieve all evidence items from the CIViC DB" />
<meta name="twitter:card" content="summary" />



<!-- mathjax -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script>

<!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->


  </head>

  <body>
    <div class="container template-reference-topic">
      <header>
      <div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">civicr</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="Released version">0.1.0</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="../index.html">
    <span class="fa fa-home fa-lg"></span>
     
  </a>
</li>
<li>
  <a href="../reference/index.html">Reference</a>
</li>
      </ul>
      
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
      
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

      
      </header>

<div class="row">
  <div class="col-md-9 contents">
    <div class="page-header">
    <h1>Get a list of evidence items</h1>
    
    <div class="hidden name"><code>getAllEvidenceItems.Rd</code></div>
    </div>

    <div class="ref-description">
    
    <p>Retrieve all evidence items from the CIViC DB</p>
    
    </div>

    <pre class="usage"><span class='fu'>getAllEvidenceItems</span>(<span class='kw'>page</span> <span class='kw'>=</span> <span class='fl'>1</span>, <span class='kw'>count</span> <span class='kw'>=</span> <span class='fl'>25</span>)</pre>
    
    <h2 class="hasAnchor" id="arguments"><a class="anchor" href="#arguments"></a>Arguments</h2>
    <table class="ref-arguments">
    <colgroup><col class="name" /><col class="desc" /></colgroup>
    <tr>
      <th>page</th>
      <td><p>the page number to retrieve</p></td>
    </tr>
    <tr>
      <th>count</th>
      <td><p>the number of evidence items to retrieve</p></td>
    </tr>
    </table>
    
    <h2 class="hasAnchor" id="value"><a class="anchor" href="#value"></a>Value</h2>

    <p>An S3 Object of type civic_api containing the content, url, and response</p>
    

    <h2 class="hasAnchor" id="examples"><a class="anchor" href="#examples"></a>Examples</h2>
    <pre class="examples"><div class='input'><span class='fu'>getAllEvidenceItems</span>(<span class='kw'>count</span> <span class='kw'>=</span> <span class='fl'>10</span>)</div><div class='output co'>#&gt; $content
#&gt; $content$`_meta`
#&gt; $content$`_meta`$current_page
#&gt; [1] 1
#&gt; 
#&gt; $content$`_meta`$per_page
#&gt; [1] "10"
#&gt; 
#&gt; $content$`_meta`$total_pages
#&gt; [1] 642
#&gt; 
#&gt; $content$`_meta`$total_count
#&gt; [1] 6411
#&gt; 
#&gt; $content$`_meta`$links
#&gt; $content$`_meta`$links$`next`
#&gt; [1] "https://civicdb.org/api/evidence_items?count=10&amp;page=2"
#&gt; 
#&gt; $content$`_meta`$links$previous
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records
#&gt; $content$records[[1]]
#&gt; $content$records[[1]]$id
#&gt; [1] 1
#&gt; 
#&gt; $content$records[[1]]$name
#&gt; [1] "EID1"
#&gt; 
#&gt; $content$records[[1]]$description
#&gt; [1] "JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL)."
#&gt; 
#&gt; $content$records[[1]]$disease
#&gt; $content$records[[1]]$disease$id
#&gt; [1] 1
#&gt; 
#&gt; $content$records[[1]]$disease$name
#&gt; [1] "Lymphoid Leukemia"
#&gt; 
#&gt; $content$records[[1]]$disease$display_name
#&gt; [1] "Lymphoid Leukemia"
#&gt; 
#&gt; $content$records[[1]]$disease$doid
#&gt; [1] "10747"
#&gt; 
#&gt; $content$records[[1]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:10747"
#&gt; 
#&gt; 
#&gt; $content$records[[1]]$drugs
#&gt; list()
#&gt; 
#&gt; $content$records[[1]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[1]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[1]]$evidence_type
#&gt; [1] "Diagnostic"
#&gt; 
#&gt; $content$records[[1]]$clinical_significance
#&gt; [1] "Negative"
#&gt; 
#&gt; $content$records[[1]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[1]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[1]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[1]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[1]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[1]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[1]]$source
#&gt; $content$records[[1]]$source$id
#&gt; [1] 51
#&gt; 
#&gt; $content$records[[1]]$source$name
#&gt; [1] "The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia."
#&gt; 
#&gt; $content$records[[1]]$source$citation
#&gt; [1] "Levine et al., 2005, Blood"
#&gt; 
#&gt; $content$records[[1]]$source$citation_id
#&gt; [1] "16081687"
#&gt; 
#&gt; $content$records[[1]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[1]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[1]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/16081687"
#&gt; 
#&gt; $content$records[[1]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[1]]$source$pmc_id
#&gt; [1] "PMC1895066"
#&gt; 
#&gt; $content$records[[1]]$source$publication_date
#&gt; $content$records[[1]]$source$publication_date$year
#&gt; [1] 2005
#&gt; 
#&gt; $content$records[[1]]$source$publication_date$month
#&gt; [1] 11
#&gt; 
#&gt; $content$records[[1]]$source$publication_date$day
#&gt; [1] 15
#&gt; 
#&gt; 
#&gt; $content$records[[1]]$source$journal
#&gt; [1] "Blood"
#&gt; 
#&gt; $content$records[[1]]$source$full_journal_title
#&gt; [1] "Blood"
#&gt; 
#&gt; $content$records[[1]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[1]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[1]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[1]]$variant_id
#&gt; [1] 64
#&gt; 
#&gt; $content$records[[1]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[2]]
#&gt; $content$records[[2]]$id
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[2]]$name
#&gt; [1] "EID2"
#&gt; 
#&gt; $content$records[[2]]$description
#&gt; [1] "GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant."
#&gt; 
#&gt; $content$records[[2]]$disease
#&gt; $content$records[[2]]$disease$id
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[2]]$disease$name
#&gt; [1] "Gastrointestinal Stromal Tumor"
#&gt; 
#&gt; $content$records[[2]]$disease$display_name
#&gt; [1] "Gastrointestinal Stromal Tumor"
#&gt; 
#&gt; $content$records[[2]]$disease$doid
#&gt; [1] "9253"
#&gt; 
#&gt; $content$records[[2]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:9253"
#&gt; 
#&gt; 
#&gt; $content$records[[2]]$drugs
#&gt; list()
#&gt; 
#&gt; $content$records[[2]]$rating
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[2]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[2]]$evidence_type
#&gt; [1] "Diagnostic"
#&gt; 
#&gt; $content$records[[2]]$clinical_significance
#&gt; [1] "Negative"
#&gt; 
#&gt; $content$records[[2]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[2]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[2]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[2]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[2]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[2]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[2]]$source
#&gt; $content$records[[2]]$source$id
#&gt; [1] 52
#&gt; 
#&gt; $content$records[[2]]$source$name
#&gt; [1] "A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential."
#&gt; 
#&gt; $content$records[[2]]$source$citation
#&gt; [1] "Lasota et al., 2004, Lab. Invest."
#&gt; 
#&gt; $content$records[[2]]$source$citation_id
#&gt; [1] "15146165"
#&gt; 
#&gt; $content$records[[2]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[2]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[2]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/15146165"
#&gt; 
#&gt; $content$records[[2]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[2]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[2]]$source$publication_date
#&gt; $content$records[[2]]$source$publication_date$year
#&gt; [1] 2004
#&gt; 
#&gt; $content$records[[2]]$source$publication_date$month
#&gt; [1] 7
#&gt; 
#&gt; 
#&gt; $content$records[[2]]$source$journal
#&gt; [1] "Lab. Invest."
#&gt; 
#&gt; $content$records[[2]]$source$full_journal_title
#&gt; [1] "Laboratory investigation; a journal of technical methods and pathology"
#&gt; 
#&gt; $content$records[[2]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[2]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[2]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[2]]$variant_id
#&gt; [1] 99
#&gt; 
#&gt; $content$records[[2]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[3]]
#&gt; $content$records[[3]]$id
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[3]]$name
#&gt; [1] "EID3"
#&gt; 
#&gt; $content$records[[3]]$description
#&gt; [1] "DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk)."
#&gt; 
#&gt; $content$records[[3]]$disease
#&gt; $content$records[[3]]$disease$id
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[3]]$disease$name
#&gt; [1] "Acute Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[3]]$disease$display_name
#&gt; [1] "Acute Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[3]]$disease$doid
#&gt; [1] "9119"
#&gt; 
#&gt; $content$records[[3]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:9119"
#&gt; 
#&gt; 
#&gt; $content$records[[3]]$drugs
#&gt; list()
#&gt; 
#&gt; $content$records[[3]]$rating
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[3]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[3]]$evidence_type
#&gt; [1] "Diagnostic"
#&gt; 
#&gt; $content$records[[3]]$clinical_significance
#&gt; [1] "Positive"
#&gt; 
#&gt; $content$records[[3]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[3]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[3]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[3]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[3]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[3]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[3]]$source
#&gt; $content$records[[3]]$source$id
#&gt; [1] 53
#&gt; 
#&gt; $content$records[[3]]$source$name
#&gt; [1] "Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience."
#&gt; 
#&gt; $content$records[[3]]$source$citation
#&gt; [1] "LaRochelle et al., 2011, Oncotarget"
#&gt; 
#&gt; $content$records[[3]]$source$citation_id
#&gt; [1] "22081665"
#&gt; 
#&gt; $content$records[[3]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[3]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[3]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/22081665"
#&gt; 
#&gt; $content$records[[3]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[3]]$source$pmc_id
#&gt; [1] "PMC3260002"
#&gt; 
#&gt; $content$records[[3]]$source$publication_date
#&gt; $content$records[[3]]$source$publication_date$year
#&gt; [1] 2011
#&gt; 
#&gt; $content$records[[3]]$source$publication_date$month
#&gt; [1] 11
#&gt; 
#&gt; 
#&gt; $content$records[[3]]$source$journal
#&gt; [1] "Oncotarget"
#&gt; 
#&gt; $content$records[[3]]$source$full_journal_title
#&gt; [1] "Oncotarget"
#&gt; 
#&gt; $content$records[[3]]$source$status
#&gt; [1] "partially curated"
#&gt; 
#&gt; $content$records[[3]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[3]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[3]]$variant_id
#&gt; [1] 32
#&gt; 
#&gt; $content$records[[3]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[4]]
#&gt; $content$records[[4]]$id
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[4]]$name
#&gt; [1] "EID4"
#&gt; 
#&gt; $content$records[[4]]$description
#&gt; [1] "Young AML patients (&lt;60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A."
#&gt; 
#&gt; $content$records[[4]]$disease
#&gt; $content$records[[4]]$disease$id
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[4]]$disease$name
#&gt; [1] "Acute Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[4]]$disease$display_name
#&gt; [1] "Acute Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[4]]$disease$doid
#&gt; [1] "9119"
#&gt; 
#&gt; $content$records[[4]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:9119"
#&gt; 
#&gt; 
#&gt; $content$records[[4]]$drugs
#&gt; list()
#&gt; 
#&gt; $content$records[[4]]$rating
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[4]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[4]]$evidence_type
#&gt; [1] "Diagnostic"
#&gt; 
#&gt; $content$records[[4]]$clinical_significance
#&gt; [1] "Positive"
#&gt; 
#&gt; $content$records[[4]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[4]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[4]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[4]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[4]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[4]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[4]]$source
#&gt; $content$records[[4]]$source$id
#&gt; [1] 54
#&gt; 
#&gt; $content$records[[4]]$source$name
#&gt; [1] "Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia."
#&gt; 
#&gt; $content$records[[4]]$source$citation
#&gt; [1] "Ribeiro et al., 2012, Blood"
#&gt; 
#&gt; $content$records[[4]]$source$citation_id
#&gt; [1] "22490330"
#&gt; 
#&gt; $content$records[[4]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[4]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[4]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/22490330"
#&gt; 
#&gt; $content$records[[4]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[4]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[4]]$source$publication_date
#&gt; $content$records[[4]]$source$publication_date$year
#&gt; [1] 2012
#&gt; 
#&gt; $content$records[[4]]$source$publication_date$month
#&gt; [1] 6
#&gt; 
#&gt; $content$records[[4]]$source$publication_date$day
#&gt; [1] 14
#&gt; 
#&gt; 
#&gt; $content$records[[4]]$source$journal
#&gt; [1] "Blood"
#&gt; 
#&gt; $content$records[[4]]$source$full_journal_title
#&gt; [1] "Blood"
#&gt; 
#&gt; $content$records[[4]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[4]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[4]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[4]]$variant_id
#&gt; [1] 32
#&gt; 
#&gt; $content$records[[4]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[5]]
#&gt; $content$records[[5]]$id
#&gt; [1] 5
#&gt; 
#&gt; $content$records[[5]]$name
#&gt; [1] "EID5"
#&gt; 
#&gt; $content$records[[5]]$description
#&gt; [1] "JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML)."
#&gt; 
#&gt; $content$records[[5]]$disease
#&gt; $content$records[[5]]$disease$id
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[5]]$disease$name
#&gt; [1] "Chronic Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[5]]$disease$display_name
#&gt; [1] "Chronic Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[5]]$disease$doid
#&gt; [1] "8552"
#&gt; 
#&gt; $content$records[[5]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:8552"
#&gt; 
#&gt; 
#&gt; $content$records[[5]]$drugs
#&gt; list()
#&gt; 
#&gt; $content$records[[5]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[5]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[5]]$evidence_type
#&gt; [1] "Diagnostic"
#&gt; 
#&gt; $content$records[[5]]$clinical_significance
#&gt; [1] "Positive"
#&gt; 
#&gt; $content$records[[5]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[5]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[5]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[5]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[5]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[5]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[5]]$source
#&gt; $content$records[[5]]$source$id
#&gt; [1] 51
#&gt; 
#&gt; $content$records[[5]]$source$name
#&gt; [1] "The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia."
#&gt; 
#&gt; $content$records[[5]]$source$citation
#&gt; [1] "Levine et al., 2005, Blood"
#&gt; 
#&gt; $content$records[[5]]$source$citation_id
#&gt; [1] "16081687"
#&gt; 
#&gt; $content$records[[5]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[5]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[5]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/16081687"
#&gt; 
#&gt; $content$records[[5]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[5]]$source$pmc_id
#&gt; [1] "PMC1895066"
#&gt; 
#&gt; $content$records[[5]]$source$publication_date
#&gt; $content$records[[5]]$source$publication_date$year
#&gt; [1] 2005
#&gt; 
#&gt; $content$records[[5]]$source$publication_date$month
#&gt; [1] 11
#&gt; 
#&gt; $content$records[[5]]$source$publication_date$day
#&gt; [1] 15
#&gt; 
#&gt; 
#&gt; $content$records[[5]]$source$journal
#&gt; [1] "Blood"
#&gt; 
#&gt; $content$records[[5]]$source$full_journal_title
#&gt; [1] "Blood"
#&gt; 
#&gt; $content$records[[5]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[5]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[5]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[5]]$variant_id
#&gt; [1] 64
#&gt; 
#&gt; $content$records[[5]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[6]]
#&gt; $content$records[[6]]$id
#&gt; [1] 7
#&gt; 
#&gt; $content$records[[6]]$name
#&gt; [1] "EID7"
#&gt; 
#&gt; $content$records[[6]]$description
#&gt; [1] "The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer."
#&gt; 
#&gt; $content$records[[6]]$disease
#&gt; $content$records[[6]]$disease$id
#&gt; [1] 5
#&gt; 
#&gt; $content$records[[6]]$disease$name
#&gt; [1] "Bone Marrow Cancer"
#&gt; 
#&gt; $content$records[[6]]$disease$display_name
#&gt; [1] "Bone Marrow Cancer"
#&gt; 
#&gt; $content$records[[6]]$disease$doid
#&gt; [1] "4960"
#&gt; 
#&gt; $content$records[[6]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:4960"
#&gt; 
#&gt; 
#&gt; $content$records[[6]]$drugs
#&gt; list()
#&gt; 
#&gt; $content$records[[6]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[6]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[6]]$evidence_type
#&gt; [1] "Diagnostic"
#&gt; 
#&gt; $content$records[[6]]$clinical_significance
#&gt; [1] "Positive"
#&gt; 
#&gt; $content$records[[6]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[6]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[6]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[6]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[6]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[6]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[6]]$source
#&gt; $content$records[[6]]$source$id
#&gt; [1] 55
#&gt; 
#&gt; $content$records[[6]]$source$name
#&gt; [1] "A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms."
#&gt; 
#&gt; $content$records[[6]]$source$citation
#&gt; [1] "Kilpivaara et al., 2009, Nat. Genet."
#&gt; 
#&gt; $content$records[[6]]$source$citation_id
#&gt; [1] "19287384"
#&gt; 
#&gt; $content$records[[6]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[6]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[6]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/19287384"
#&gt; 
#&gt; $content$records[[6]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[6]]$source$pmc_id
#&gt; [1] "PMC3676425"
#&gt; 
#&gt; $content$records[[6]]$source$publication_date
#&gt; $content$records[[6]]$source$publication_date$year
#&gt; [1] 2009
#&gt; 
#&gt; $content$records[[6]]$source$publication_date$month
#&gt; [1] 4
#&gt; 
#&gt; 
#&gt; $content$records[[6]]$source$journal
#&gt; [1] "Nat. Genet."
#&gt; 
#&gt; $content$records[[6]]$source$full_journal_title
#&gt; [1] "Nature genetics"
#&gt; 
#&gt; $content$records[[6]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[6]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[6]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[6]]$variant_id
#&gt; [1] 64
#&gt; 
#&gt; $content$records[[6]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[7]]
#&gt; $content$records[[7]]$id
#&gt; [1] 8
#&gt; 
#&gt; $content$records[[7]]$name
#&gt; [1] "EID8"
#&gt; 
#&gt; $content$records[[7]]$description
#&gt; [1] "Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation."
#&gt; 
#&gt; $content$records[[7]]$disease
#&gt; $content$records[[7]]$disease$id
#&gt; [1] 6
#&gt; 
#&gt; $content$records[[7]]$disease$name
#&gt; [1] "Acute Leukemia"
#&gt; 
#&gt; $content$records[[7]]$disease$display_name
#&gt; [1] "Acute Leukemia"
#&gt; 
#&gt; $content$records[[7]]$disease$doid
#&gt; [1] "12603"
#&gt; 
#&gt; $content$records[[7]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:12603"
#&gt; 
#&gt; 
#&gt; $content$records[[7]]$drugs
#&gt; list()
#&gt; 
#&gt; $content$records[[7]]$rating
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[7]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[7]]$evidence_type
#&gt; [1] "Diagnostic"
#&gt; 
#&gt; $content$records[[7]]$clinical_significance
#&gt; [1] "Positive"
#&gt; 
#&gt; $content$records[[7]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[7]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[7]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[7]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[7]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[7]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[7]]$source
#&gt; $content$records[[7]]$source$id
#&gt; [1] 56
#&gt; 
#&gt; $content$records[[7]]$source$name
#&gt; [1] "RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures."
#&gt; 
#&gt; $content$records[[7]]$source$citation
#&gt; [1] "Andrade et al., 2014, BMC Cancer"
#&gt; 
#&gt; $content$records[[7]]$source$citation_id
#&gt; [1] "24571676"
#&gt; 
#&gt; $content$records[[7]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[7]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[7]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/24571676"
#&gt; 
#&gt; $content$records[[7]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[7]]$source$pmc_id
#&gt; [1] "PMC3946262"
#&gt; 
#&gt; $content$records[[7]]$source$publication_date
#&gt; $content$records[[7]]$source$publication_date$year
#&gt; [1] 2014
#&gt; 
#&gt; 
#&gt; $content$records[[7]]$source$journal
#&gt; [1] "BMC Cancer"
#&gt; 
#&gt; $content$records[[7]]$source$full_journal_title
#&gt; [1] "BMC cancer"
#&gt; 
#&gt; $content$records[[7]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[7]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[7]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[7]]$variant_id
#&gt; [1] 76
#&gt; 
#&gt; $content$records[[7]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[8]]
#&gt; $content$records[[8]]$id
#&gt; [1] 10
#&gt; 
#&gt; $content$records[[8]]$name
#&gt; [1] "EID10"
#&gt; 
#&gt; $content$records[[8]]$description
#&gt; [1] "Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk."
#&gt; 
#&gt; $content$records[[8]]$disease
#&gt; $content$records[[8]]$disease$id
#&gt; [1] 7
#&gt; 
#&gt; $content$records[[8]]$disease$name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[8]]$disease$display_name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[8]]$disease$doid
#&gt; [1] "1909"
#&gt; 
#&gt; $content$records[[8]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:1909"
#&gt; 
#&gt; 
#&gt; $content$records[[8]]$drugs
#&gt; list()
#&gt; 
#&gt; $content$records[[8]]$rating
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[8]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[8]]$evidence_type
#&gt; [1] "Diagnostic"
#&gt; 
#&gt; $content$records[[8]]$clinical_significance
#&gt; [1] "Positive"
#&gt; 
#&gt; $content$records[[8]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[8]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[8]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[8]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[8]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[8]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[8]]$source
#&gt; $content$records[[8]]$source$id
#&gt; [1] 57
#&gt; 
#&gt; $content$records[[8]]$source$name
#&gt; [1] "NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi."
#&gt; 
#&gt; $content$records[[8]]$source$citation
#&gt; [1] "Tschandl et al., 2013, PLoS ONE"
#&gt; 
#&gt; $content$records[[8]]$source$citation_id
#&gt; [1] "23861977"
#&gt; 
#&gt; $content$records[[8]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[8]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[8]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/23861977"
#&gt; 
#&gt; $content$records[[8]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[8]]$source$pmc_id
#&gt; [1] "PMC3704624"
#&gt; 
#&gt; $content$records[[8]]$source$publication_date
#&gt; $content$records[[8]]$source$publication_date$year
#&gt; [1] 2013
#&gt; 
#&gt; 
#&gt; $content$records[[8]]$source$journal
#&gt; [1] "PLoS ONE"
#&gt; 
#&gt; $content$records[[8]]$source$full_journal_title
#&gt; [1] "PloS one"
#&gt; 
#&gt; $content$records[[8]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[8]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[8]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[8]]$variant_id
#&gt; [1] 94
#&gt; 
#&gt; $content$records[[8]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[9]]
#&gt; $content$records[[9]]$id
#&gt; [1] 11
#&gt; 
#&gt; $content$records[[9]]$name
#&gt; [1] "EID11"
#&gt; 
#&gt; $content$records[[9]]$description
#&gt; [1] "Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation."
#&gt; 
#&gt; $content$records[[9]]$disease
#&gt; $content$records[[9]]$disease$id
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[9]]$disease$name
#&gt; [1] "Acute Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[9]]$disease$display_name
#&gt; [1] "Acute Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[9]]$disease$doid
#&gt; [1] "9119"
#&gt; 
#&gt; $content$records[[9]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:9119"
#&gt; 
#&gt; 
#&gt; $content$records[[9]]$drugs
#&gt; $content$records[[9]]$drugs[[1]]
#&gt; $content$records[[9]]$drugs[[1]]$id
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[9]]$drugs[[1]]$name
#&gt; [1] "Daunorubicin"
#&gt; 
#&gt; $content$records[[9]]$drugs[[1]]$pubchem_id
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[9]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[9]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[9]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[9]]$clinical_significance
#&gt; [1] "Resistance"
#&gt; 
#&gt; $content$records[[9]]$evidence_direction
#&gt; [1] "Does Not Support"
#&gt; 
#&gt; $content$records[[9]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[9]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[9]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[9]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[9]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[9]]$source
#&gt; $content$records[[9]]$source$id
#&gt; [1] 53
#&gt; 
#&gt; $content$records[[9]]$source$name
#&gt; [1] "Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience."
#&gt; 
#&gt; $content$records[[9]]$source$citation
#&gt; [1] "LaRochelle et al., 2011, Oncotarget"
#&gt; 
#&gt; $content$records[[9]]$source$citation_id
#&gt; [1] "22081665"
#&gt; 
#&gt; $content$records[[9]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[9]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[9]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/22081665"
#&gt; 
#&gt; $content$records[[9]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[9]]$source$pmc_id
#&gt; [1] "PMC3260002"
#&gt; 
#&gt; $content$records[[9]]$source$publication_date
#&gt; $content$records[[9]]$source$publication_date$year
#&gt; [1] 2011
#&gt; 
#&gt; $content$records[[9]]$source$publication_date$month
#&gt; [1] 11
#&gt; 
#&gt; 
#&gt; $content$records[[9]]$source$journal
#&gt; [1] "Oncotarget"
#&gt; 
#&gt; $content$records[[9]]$source$full_journal_title
#&gt; [1] "Oncotarget"
#&gt; 
#&gt; $content$records[[9]]$source$status
#&gt; [1] "partially curated"
#&gt; 
#&gt; $content$records[[9]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[9]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[9]]$variant_id
#&gt; [1] 32
#&gt; 
#&gt; $content$records[[9]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[10]]
#&gt; $content$records[[10]]$id
#&gt; [1] 12
#&gt; 
#&gt; $content$records[[10]]$name
#&gt; [1] "EID12"
#&gt; 
#&gt; $content$records[[10]]$description
#&gt; [1] "A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells."
#&gt; 
#&gt; $content$records[[10]]$disease
#&gt; $content$records[[10]]$disease$id
#&gt; [1] 7
#&gt; 
#&gt; $content$records[[10]]$disease$name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[10]]$disease$display_name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[10]]$disease$doid
#&gt; [1] "1909"
#&gt; 
#&gt; $content$records[[10]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:1909"
#&gt; 
#&gt; 
#&gt; $content$records[[10]]$drugs
#&gt; $content$records[[10]]$drugs[[1]]
#&gt; $content$records[[10]]$drugs[[1]]$id
#&gt; [1] 122
#&gt; 
#&gt; $content$records[[10]]$drugs[[1]]$name
#&gt; [1] "Selumetinib"
#&gt; 
#&gt; $content$records[[10]]$drugs[[1]]$pubchem_id
#&gt; [1] ""
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[10]]$rating
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[10]]$evidence_level
#&gt; [1] "D"
#&gt; 
#&gt; $content$records[[10]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[10]]$clinical_significance
#&gt; [1] "Resistance"
#&gt; 
#&gt; $content$records[[10]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[10]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[10]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[10]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[10]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[10]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[10]]$source
#&gt; $content$records[[10]]$source$id
#&gt; [1] 58
#&gt; 
#&gt; $content$records[[10]]$source$name
#&gt; [1] "MEK1 mutations confer resistance to MEK and B-RAF inhibition."
#&gt; 
#&gt; $content$records[[10]]$source$citation
#&gt; [1] "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A."
#&gt; 
#&gt; $content$records[[10]]$source$citation_id
#&gt; [1] "19915144"
#&gt; 
#&gt; $content$records[[10]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[10]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[10]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
#&gt; 
#&gt; $content$records[[10]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[10]]$source$pmc_id
#&gt; [1] "PMC2777185"
#&gt; 
#&gt; $content$records[[10]]$source$publication_date
#&gt; $content$records[[10]]$source$publication_date$year
#&gt; [1] 2009
#&gt; 
#&gt; $content$records[[10]]$source$publication_date$month
#&gt; [1] 12
#&gt; 
#&gt; $content$records[[10]]$source$publication_date$day
#&gt; [1] 1
#&gt; 
#&gt; 
#&gt; $content$records[[10]]$source$journal
#&gt; [1] "Proc. Natl. Acad. Sci. U.S.A."
#&gt; 
#&gt; $content$records[[10]]$source$full_journal_title
#&gt; [1] "Proceedings of the National Academy of Sciences of the United States of America"
#&gt; 
#&gt; $content$records[[10]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[10]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[10]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[10]]$variant_id
#&gt; [1] 82
#&gt; 
#&gt; $content$records[[10]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; 
#&gt; 
#&gt; $url
#&gt; [1] "https://civicdb.org/api/evidence_items"
#&gt; 
#&gt; $response
#&gt; Response [https://civicdb.org/api/evidence_items?page=1&amp;count=10]
#&gt;   Date: 2019-09-03 16:44
#&gt;   Status: 200
#&gt;   Content-Type: application/json; charset=utf-8
#&gt;   Size: 12.1 kB
#&gt; 
#&gt; 
#&gt; attr(,"class")
#&gt; [1] "civic_api"</div><div class='input'><span class='fu'>getAllEvidenceItems</span>(<span class='kw'>page</span> <span class='kw'>=</span> <span class='fl'>2</span>, <span class='kw'>count</span> <span class='kw'>=</span> <span class='fl'>10</span>)</div><div class='output co'>#&gt; $content
#&gt; $content$`_meta`
#&gt; $content$`_meta`$current_page
#&gt; [1] 2
#&gt; 
#&gt; $content$`_meta`$per_page
#&gt; [1] "10"
#&gt; 
#&gt; $content$`_meta`$total_pages
#&gt; [1] 642
#&gt; 
#&gt; $content$`_meta`$total_count
#&gt; [1] 6411
#&gt; 
#&gt; $content$`_meta`$links
#&gt; $content$`_meta`$links$`next`
#&gt; [1] "https://civicdb.org/api/evidence_items?count=10&amp;page=3"
#&gt; 
#&gt; $content$`_meta`$links$previous
#&gt; [1] "https://civicdb.org/api/evidence_items?count=10&amp;page=1"
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records
#&gt; $content$records[[1]]
#&gt; $content$records[[1]]$id
#&gt; [1] 13
#&gt; 
#&gt; $content$records[[1]]$name
#&gt; [1] "EID13"
#&gt; 
#&gt; $content$records[[1]]$description
#&gt; [1] "A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells."
#&gt; 
#&gt; $content$records[[1]]$disease
#&gt; $content$records[[1]]$disease$id
#&gt; [1] 7
#&gt; 
#&gt; $content$records[[1]]$disease$name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[1]]$disease$display_name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[1]]$disease$doid
#&gt; [1] "1909"
#&gt; 
#&gt; $content$records[[1]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:1909"
#&gt; 
#&gt; 
#&gt; $content$records[[1]]$drugs
#&gt; $content$records[[1]]$drugs[[1]]
#&gt; $content$records[[1]]$drugs[[1]]$id
#&gt; [1] 122
#&gt; 
#&gt; $content$records[[1]]$drugs[[1]]$name
#&gt; [1] "Selumetinib"
#&gt; 
#&gt; $content$records[[1]]$drugs[[1]]$pubchem_id
#&gt; [1] ""
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[1]]$rating
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[1]]$evidence_level
#&gt; [1] "D"
#&gt; 
#&gt; $content$records[[1]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[1]]$clinical_significance
#&gt; [1] "Resistance"
#&gt; 
#&gt; $content$records[[1]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[1]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[1]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[1]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[1]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[1]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[1]]$source
#&gt; $content$records[[1]]$source$id
#&gt; [1] 58
#&gt; 
#&gt; $content$records[[1]]$source$name
#&gt; [1] "MEK1 mutations confer resistance to MEK and B-RAF inhibition."
#&gt; 
#&gt; $content$records[[1]]$source$citation
#&gt; [1] "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A."
#&gt; 
#&gt; $content$records[[1]]$source$citation_id
#&gt; [1] "19915144"
#&gt; 
#&gt; $content$records[[1]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[1]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[1]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
#&gt; 
#&gt; $content$records[[1]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[1]]$source$pmc_id
#&gt; [1] "PMC2777185"
#&gt; 
#&gt; $content$records[[1]]$source$publication_date
#&gt; $content$records[[1]]$source$publication_date$year
#&gt; [1] 2009
#&gt; 
#&gt; $content$records[[1]]$source$publication_date$month
#&gt; [1] 12
#&gt; 
#&gt; $content$records[[1]]$source$publication_date$day
#&gt; [1] 1
#&gt; 
#&gt; 
#&gt; $content$records[[1]]$source$journal
#&gt; [1] "Proc. Natl. Acad. Sci. U.S.A."
#&gt; 
#&gt; $content$records[[1]]$source$full_journal_title
#&gt; [1] "Proceedings of the National Academy of Sciences of the United States of America"
#&gt; 
#&gt; $content$records[[1]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[1]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[1]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[1]]$variant_id
#&gt; [1] 83
#&gt; 
#&gt; $content$records[[1]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[2]]
#&gt; $content$records[[2]]$id
#&gt; [1] 14
#&gt; 
#&gt; $content$records[[2]]$name
#&gt; [1] "EID14"
#&gt; 
#&gt; $content$records[[2]]$description
#&gt; [1] "Vemurafenib resistance is associated with gain of Q61 mutation in NRAS."
#&gt; 
#&gt; $content$records[[2]]$disease
#&gt; $content$records[[2]]$disease$id
#&gt; [1] 7
#&gt; 
#&gt; $content$records[[2]]$disease$name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[2]]$disease$display_name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[2]]$disease$doid
#&gt; [1] "1909"
#&gt; 
#&gt; $content$records[[2]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:1909"
#&gt; 
#&gt; 
#&gt; $content$records[[2]]$drugs
#&gt; $content$records[[2]]$drugs[[1]]
#&gt; $content$records[[2]]$drugs[[1]]$id
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[2]]$drugs[[1]]$name
#&gt; [1] "Vemurafenib"
#&gt; 
#&gt; $content$records[[2]]$drugs[[1]]$pubchem_id
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[2]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[2]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[2]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[2]]$clinical_significance
#&gt; [1] "Resistance"
#&gt; 
#&gt; $content$records[[2]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[2]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[2]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[2]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[2]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[2]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[2]]$source
#&gt; $content$records[[2]]$source$id
#&gt; [1] 60
#&gt; 
#&gt; $content$records[[2]]$source$name
#&gt; [1] "Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma."
#&gt; 
#&gt; $content$records[[2]]$source$citation
#&gt; [1] "Trunzer et al., 2013, J. Clin. Oncol."
#&gt; 
#&gt; $content$records[[2]]$source$citation_id
#&gt; [1] "23569304"
#&gt; 
#&gt; $content$records[[2]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[2]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[2]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/23569304"
#&gt; 
#&gt; $content$records[[2]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[2]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[2]]$source$publication_date
#&gt; $content$records[[2]]$source$publication_date$year
#&gt; [1] 2013
#&gt; 
#&gt; $content$records[[2]]$source$publication_date$month
#&gt; [1] 5
#&gt; 
#&gt; $content$records[[2]]$source$publication_date$day
#&gt; [1] 10
#&gt; 
#&gt; 
#&gt; $content$records[[2]]$source$journal
#&gt; [1] "J. Clin. Oncol."
#&gt; 
#&gt; $content$records[[2]]$source$full_journal_title
#&gt; [1] "Journal of clinical oncology : official journal of the American Society of Clinical Oncology"
#&gt; 
#&gt; $content$records[[2]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[2]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[2]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[2]]$variant_id
#&gt; [1] 94
#&gt; 
#&gt; $content$records[[2]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[3]]
#&gt; $content$records[[3]]$id
#&gt; [1] 15
#&gt; 
#&gt; $content$records[[3]]$name
#&gt; [1] "EID15"
#&gt; 
#&gt; $content$records[[3]]$description
#&gt; [1] "GIST cancer with D842V mutation is resistant to imatinib."
#&gt; 
#&gt; $content$records[[3]]$disease
#&gt; $content$records[[3]]$disease$id
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[3]]$disease$name
#&gt; [1] "Gastrointestinal Stromal Tumor"
#&gt; 
#&gt; $content$records[[3]]$disease$display_name
#&gt; [1] "Gastrointestinal Stromal Tumor"
#&gt; 
#&gt; $content$records[[3]]$disease$doid
#&gt; [1] "9253"
#&gt; 
#&gt; $content$records[[3]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:9253"
#&gt; 
#&gt; 
#&gt; $content$records[[3]]$drugs
#&gt; $content$records[[3]]$drugs[[1]]
#&gt; $content$records[[3]]$drugs[[1]]$id
#&gt; [1] 5
#&gt; 
#&gt; $content$records[[3]]$drugs[[1]]$name
#&gt; [1] "Imatinib"
#&gt; 
#&gt; $content$records[[3]]$drugs[[1]]$pubchem_id
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[3]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[3]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[3]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[3]]$clinical_significance
#&gt; [1] "Resistance"
#&gt; 
#&gt; $content$records[[3]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[3]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[3]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[3]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[3]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[3]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[3]]$source
#&gt; $content$records[[3]]$source$id
#&gt; [1] 61
#&gt; 
#&gt; $content$records[[3]]$source$name
#&gt; [1] "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib."
#&gt; 
#&gt; $content$records[[3]]$source$citation
#&gt; [1] "Corless et al., 2005, J. Clin. Oncol."
#&gt; 
#&gt; $content$records[[3]]$source$citation_id
#&gt; [1] "15928335"
#&gt; 
#&gt; $content$records[[3]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[3]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[3]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/15928335"
#&gt; 
#&gt; $content$records[[3]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[3]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[3]]$source$publication_date
#&gt; $content$records[[3]]$source$publication_date$year
#&gt; [1] 2005
#&gt; 
#&gt; $content$records[[3]]$source$publication_date$month
#&gt; [1] 8
#&gt; 
#&gt; $content$records[[3]]$source$publication_date$day
#&gt; [1] 10
#&gt; 
#&gt; 
#&gt; $content$records[[3]]$source$journal
#&gt; [1] "J. Clin. Oncol."
#&gt; 
#&gt; $content$records[[3]]$source$full_journal_title
#&gt; [1] "Journal of clinical oncology : official journal of the American Society of Clinical Oncology"
#&gt; 
#&gt; $content$records[[3]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[3]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[3]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[3]]$variant_id
#&gt; [1] 99
#&gt; 
#&gt; $content$records[[3]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[4]]
#&gt; $content$records[[4]]$id
#&gt; [1] 16
#&gt; 
#&gt; $content$records[[4]]$name
#&gt; [1] "EID16"
#&gt; 
#&gt; $content$records[[4]]$description
#&gt; [1] "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib."
#&gt; 
#&gt; $content$records[[4]]$disease
#&gt; $content$records[[4]]$disease$id
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[4]]$disease$name
#&gt; [1] "Gastrointestinal Stromal Tumor"
#&gt; 
#&gt; $content$records[[4]]$disease$display_name
#&gt; [1] "Gastrointestinal Stromal Tumor"
#&gt; 
#&gt; $content$records[[4]]$disease$doid
#&gt; [1] "9253"
#&gt; 
#&gt; $content$records[[4]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:9253"
#&gt; 
#&gt; 
#&gt; $content$records[[4]]$drugs
#&gt; $content$records[[4]]$drugs[[1]]
#&gt; $content$records[[4]]$drugs[[1]]$id
#&gt; [1] 5
#&gt; 
#&gt; $content$records[[4]]$drugs[[1]]$name
#&gt; [1] "Imatinib"
#&gt; 
#&gt; $content$records[[4]]$drugs[[1]]$pubchem_id
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[4]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[4]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[4]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[4]]$clinical_significance
#&gt; [1] "Resistance"
#&gt; 
#&gt; $content$records[[4]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[4]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[4]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[4]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[4]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[4]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[4]]$source
#&gt; $content$records[[4]]$source$id
#&gt; [1] 62
#&gt; 
#&gt; $content$records[[4]]$source$name
#&gt; [1] "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors."
#&gt; 
#&gt; $content$records[[4]]$source$citation
#&gt; [1] "Heinrich et al., 2006, J. Clin. Oncol."
#&gt; 
#&gt; $content$records[[4]]$source$citation_id
#&gt; [1] "16954519"
#&gt; 
#&gt; $content$records[[4]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[4]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[4]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/16954519"
#&gt; 
#&gt; $content$records[[4]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[4]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[4]]$source$publication_date
#&gt; $content$records[[4]]$source$publication_date$year
#&gt; [1] 2006
#&gt; 
#&gt; $content$records[[4]]$source$publication_date$month
#&gt; [1] 10
#&gt; 
#&gt; $content$records[[4]]$source$publication_date$day
#&gt; [1] 10
#&gt; 
#&gt; 
#&gt; $content$records[[4]]$source$journal
#&gt; [1] "J. Clin. Oncol."
#&gt; 
#&gt; $content$records[[4]]$source$full_journal_title
#&gt; [1] "Journal of clinical oncology : official journal of the American Society of Clinical Oncology"
#&gt; 
#&gt; $content$records[[4]]$source$status
#&gt; [1] "partially curated"
#&gt; 
#&gt; $content$records[[4]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[4]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[4]]$variant_id
#&gt; [1] 99
#&gt; 
#&gt; $content$records[[4]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[5]]
#&gt; $content$records[[5]]$id
#&gt; [1] 17
#&gt; 
#&gt; $content$records[[5]]$name
#&gt; [1] "EID17"
#&gt; 
#&gt; $content$records[[5]]$description
#&gt; [1] "In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission."
#&gt; 
#&gt; $content$records[[5]]$disease
#&gt; $content$records[[5]]$disease$id
#&gt; [1] 8
#&gt; 
#&gt; $content$records[[5]]$disease$name
#&gt; [1] "Lung Non-small Cell Carcinoma"
#&gt; 
#&gt; $content$records[[5]]$disease$display_name
#&gt; [1] "Lung Non-small Cell Carcinoma"
#&gt; 
#&gt; $content$records[[5]]$disease$doid
#&gt; [1] "3908"
#&gt; 
#&gt; $content$records[[5]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:3908"
#&gt; 
#&gt; 
#&gt; $content$records[[5]]$drugs
#&gt; $content$records[[5]]$drugs[[1]]
#&gt; $content$records[[5]]$drugs[[1]]$id
#&gt; [1] 6
#&gt; 
#&gt; $content$records[[5]]$drugs[[1]]$name
#&gt; [1] "Sorafenib"
#&gt; 
#&gt; $content$records[[5]]$drugs[[1]]$pubchem_id
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[5]]$rating
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[5]]$evidence_level
#&gt; [1] "C"
#&gt; 
#&gt; $content$records[[5]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[5]]$clinical_significance
#&gt; [1] "Sensitivity/Response"
#&gt; 
#&gt; $content$records[[5]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[5]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[5]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[5]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[5]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[5]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[5]]$source
#&gt; $content$records[[5]]$source$id
#&gt; [1] 6
#&gt; 
#&gt; $content$records[[5]]$source$name
#&gt; [1] "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma."
#&gt; 
#&gt; $content$records[[5]]$source$citation
#&gt; [1] "Imielinski et al., 2014, J. Clin. Invest."
#&gt; 
#&gt; $content$records[[5]]$source$citation_id
#&gt; [1] "24569458"
#&gt; 
#&gt; $content$records[[5]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[5]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[5]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/24569458"
#&gt; 
#&gt; $content$records[[5]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[5]]$source$pmc_id
#&gt; [1] "PMC3973082"
#&gt; 
#&gt; $content$records[[5]]$source$publication_date
#&gt; $content$records[[5]]$source$publication_date$year
#&gt; [1] 2014
#&gt; 
#&gt; $content$records[[5]]$source$publication_date$month
#&gt; [1] 4
#&gt; 
#&gt; 
#&gt; $content$records[[5]]$source$journal
#&gt; [1] "J. Clin. Invest."
#&gt; 
#&gt; $content$records[[5]]$source$full_journal_title
#&gt; [1] "The Journal of clinical investigation"
#&gt; 
#&gt; $content$records[[5]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[5]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[5]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[5]]$variant_id
#&gt; [1] 10
#&gt; 
#&gt; $content$records[[5]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[6]]
#&gt; $content$records[[6]]$id
#&gt; [1] 18
#&gt; 
#&gt; $content$records[[6]]$name
#&gt; [1] "EID18"
#&gt; 
#&gt; $content$records[[6]]$description
#&gt; [1] "Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation."
#&gt; 
#&gt; $content$records[[6]]$disease
#&gt; $content$records[[6]]$disease$id
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[6]]$disease$name
#&gt; [1] "Acute Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[6]]$disease$display_name
#&gt; [1] "Acute Myeloid Leukemia"
#&gt; 
#&gt; $content$records[[6]]$disease$doid
#&gt; [1] "9119"
#&gt; 
#&gt; $content$records[[6]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:9119"
#&gt; 
#&gt; 
#&gt; $content$records[[6]]$drugs
#&gt; $content$records[[6]]$drugs[[1]]
#&gt; $content$records[[6]]$drugs[[1]]$id
#&gt; [1] 7
#&gt; 
#&gt; $content$records[[6]]$drugs[[1]]$name
#&gt; [1] "Idarubicin"
#&gt; 
#&gt; $content$records[[6]]$drugs[[1]]$pubchem_id
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[6]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[6]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[6]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[6]]$clinical_significance
#&gt; [1] "Sensitivity/Response"
#&gt; 
#&gt; $content$records[[6]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[6]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[6]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[6]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[6]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[6]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[6]]$source
#&gt; $content$records[[6]]$source$id
#&gt; [1] 53
#&gt; 
#&gt; $content$records[[6]]$source$name
#&gt; [1] "Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience."
#&gt; 
#&gt; $content$records[[6]]$source$citation
#&gt; [1] "LaRochelle et al., 2011, Oncotarget"
#&gt; 
#&gt; $content$records[[6]]$source$citation_id
#&gt; [1] "22081665"
#&gt; 
#&gt; $content$records[[6]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[6]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[6]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/22081665"
#&gt; 
#&gt; $content$records[[6]]$source$open_access
#&gt; [1] TRUE
#&gt; 
#&gt; $content$records[[6]]$source$pmc_id
#&gt; [1] "PMC3260002"
#&gt; 
#&gt; $content$records[[6]]$source$publication_date
#&gt; $content$records[[6]]$source$publication_date$year
#&gt; [1] 2011
#&gt; 
#&gt; $content$records[[6]]$source$publication_date$month
#&gt; [1] 11
#&gt; 
#&gt; 
#&gt; $content$records[[6]]$source$journal
#&gt; [1] "Oncotarget"
#&gt; 
#&gt; $content$records[[6]]$source$full_journal_title
#&gt; [1] "Oncotarget"
#&gt; 
#&gt; $content$records[[6]]$source$status
#&gt; [1] "partially curated"
#&gt; 
#&gt; $content$records[[6]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[6]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[6]]$variant_id
#&gt; [1] 32
#&gt; 
#&gt; $content$records[[6]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[7]]
#&gt; $content$records[[7]]$id
#&gt; [1] 19
#&gt; 
#&gt; $content$records[[7]]$name
#&gt; [1] "EID19"
#&gt; 
#&gt; $content$records[[7]]$description
#&gt; [1] "In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F."
#&gt; 
#&gt; $content$records[[7]]$disease
#&gt; $content$records[[7]]$disease$id
#&gt; [1] 9
#&gt; 
#&gt; $content$records[[7]]$disease$name
#&gt; [1] "Polycythemia Vera"
#&gt; 
#&gt; $content$records[[7]]$disease$display_name
#&gt; [1] "Polycythemia Vera"
#&gt; 
#&gt; $content$records[[7]]$disease$doid
#&gt; [1] "8997"
#&gt; 
#&gt; $content$records[[7]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:8997"
#&gt; 
#&gt; 
#&gt; $content$records[[7]]$drugs
#&gt; $content$records[[7]]$drugs[[1]]
#&gt; $content$records[[7]]$drugs[[1]]$id
#&gt; [1] 8
#&gt; 
#&gt; $content$records[[7]]$drugs[[1]]$name
#&gt; [1] "Pegylated IFN-alpha-2a"
#&gt; 
#&gt; $content$records[[7]]$drugs[[1]]$pubchem_id
#&gt; [1] ""
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[7]]$rating
#&gt; [1] 4
#&gt; 
#&gt; $content$records[[7]]$evidence_level
#&gt; [1] "B"
#&gt; 
#&gt; $content$records[[7]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[7]]$clinical_significance
#&gt; [1] "Sensitivity/Response"
#&gt; 
#&gt; $content$records[[7]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[7]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[7]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[7]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[7]]$open_change_count
#&gt; [1] 1
#&gt; 
#&gt; $content$records[[7]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[7]]$source
#&gt; $content$records[[7]]$source$id
#&gt; [1] 64
#&gt; 
#&gt; $content$records[[7]]$source$name
#&gt; [1] "High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a."
#&gt; 
#&gt; $content$records[[7]]$source$citation
#&gt; [1] "Kiladjian et al., 2006, Blood"
#&gt; 
#&gt; $content$records[[7]]$source$citation_id
#&gt; [1] "16709929"
#&gt; 
#&gt; $content$records[[7]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[7]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[7]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/16709929"
#&gt; 
#&gt; $content$records[[7]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[7]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[7]]$source$publication_date
#&gt; $content$records[[7]]$source$publication_date$year
#&gt; [1] 2006
#&gt; 
#&gt; $content$records[[7]]$source$publication_date$month
#&gt; [1] 9
#&gt; 
#&gt; $content$records[[7]]$source$publication_date$day
#&gt; [1] 15
#&gt; 
#&gt; 
#&gt; $content$records[[7]]$source$journal
#&gt; [1] "Blood"
#&gt; 
#&gt; $content$records[[7]]$source$full_journal_title
#&gt; [1] "Blood"
#&gt; 
#&gt; $content$records[[7]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[7]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[7]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[7]]$variant_id
#&gt; [1] 64
#&gt; 
#&gt; $content$records[[7]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[8]]
#&gt; $content$records[[8]]$id
#&gt; [1] 20
#&gt; 
#&gt; $content$records[[8]]$name
#&gt; [1] "EID20"
#&gt; 
#&gt; $content$records[[8]]$description
#&gt; [1] "TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells."
#&gt; 
#&gt; $content$records[[8]]$disease
#&gt; $content$records[[8]]$disease$id
#&gt; [1] 9
#&gt; 
#&gt; $content$records[[8]]$disease$name
#&gt; [1] "Polycythemia Vera"
#&gt; 
#&gt; $content$records[[8]]$disease$display_name
#&gt; [1] "Polycythemia Vera"
#&gt; 
#&gt; $content$records[[8]]$disease$doid
#&gt; [1] "8997"
#&gt; 
#&gt; $content$records[[8]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:8997"
#&gt; 
#&gt; 
#&gt; $content$records[[8]]$drugs
#&gt; $content$records[[8]]$drugs[[1]]
#&gt; $content$records[[8]]$drugs[[1]]$id
#&gt; [1] 9
#&gt; 
#&gt; $content$records[[8]]$drugs[[1]]$name
#&gt; [1] "TG101348"
#&gt; 
#&gt; $content$records[[8]]$drugs[[1]]$pubchem_id
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[8]]$rating
#&gt; [1] 3
#&gt; 
#&gt; $content$records[[8]]$evidence_level
#&gt; [1] "D"
#&gt; 
#&gt; $content$records[[8]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[8]]$clinical_significance
#&gt; [1] "Sensitivity/Response"
#&gt; 
#&gt; $content$records[[8]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[8]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[8]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[8]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[8]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[8]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[8]]$source
#&gt; $content$records[[8]]$source$id
#&gt; [1] 65
#&gt; 
#&gt; $content$records[[8]]$source$name
#&gt; [1] "Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera."
#&gt; 
#&gt; $content$records[[8]]$source$citation
#&gt; [1] "Wernig et al., 2008, Cancer Cell"
#&gt; 
#&gt; $content$records[[8]]$source$citation_id
#&gt; [1] "18394554"
#&gt; 
#&gt; $content$records[[8]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[8]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[8]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/18394554"
#&gt; 
#&gt; $content$records[[8]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[8]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[8]]$source$publication_date
#&gt; $content$records[[8]]$source$publication_date$year
#&gt; [1] 2008
#&gt; 
#&gt; $content$records[[8]]$source$publication_date$month
#&gt; [1] 4
#&gt; 
#&gt; 
#&gt; $content$records[[8]]$source$journal
#&gt; [1] "Cancer Cell"
#&gt; 
#&gt; $content$records[[8]]$source$full_journal_title
#&gt; [1] "Cancer cell"
#&gt; 
#&gt; $content$records[[8]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[8]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[8]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[8]]$variant_id
#&gt; [1] 64
#&gt; 
#&gt; $content$records[[8]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[9]]
#&gt; $content$records[[9]]$id
#&gt; [1] 21
#&gt; 
#&gt; $content$records[[9]]$name
#&gt; [1] "EID21"
#&gt; 
#&gt; $content$records[[9]]$description
#&gt; [1] "Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation."
#&gt; 
#&gt; $content$records[[9]]$disease
#&gt; $content$records[[9]]$disease$id
#&gt; [1] 7
#&gt; 
#&gt; $content$records[[9]]$disease$name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[9]]$disease$display_name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[9]]$disease$doid
#&gt; [1] "1909"
#&gt; 
#&gt; $content$records[[9]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:1909"
#&gt; 
#&gt; 
#&gt; $content$records[[9]]$drugs
#&gt; $content$records[[9]]$drugs[[1]]
#&gt; $content$records[[9]]$drugs[[1]]$id
#&gt; [1] 10
#&gt; 
#&gt; $content$records[[9]]$drugs[[1]]$name
#&gt; [1] "17-AAG"
#&gt; 
#&gt; $content$records[[9]]$drugs[[1]]$pubchem_id
#&gt; NULL
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[9]]$rating
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[9]]$evidence_level
#&gt; [1] "C"
#&gt; 
#&gt; $content$records[[9]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[9]]$clinical_significance
#&gt; [1] "Sensitivity/Response"
#&gt; 
#&gt; $content$records[[9]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[9]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[9]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[9]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[9]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[9]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[9]]$source
#&gt; $content$records[[9]]$source$id
#&gt; [1] 66
#&gt; 
#&gt; $content$records[[9]]$source$name
#&gt; [1] "BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors."
#&gt; 
#&gt; $content$records[[9]]$source$citation
#&gt; [1] "Banerji et al., 2008, Mol. Cancer Ther."
#&gt; 
#&gt; $content$records[[9]]$source$citation_id
#&gt; [1] "18375819"
#&gt; 
#&gt; $content$records[[9]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[9]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[9]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/18375819"
#&gt; 
#&gt; $content$records[[9]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[9]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[9]]$source$publication_date
#&gt; $content$records[[9]]$source$publication_date$year
#&gt; [1] 2008
#&gt; 
#&gt; $content$records[[9]]$source$publication_date$month
#&gt; [1] 4
#&gt; 
#&gt; 
#&gt; $content$records[[9]]$source$journal
#&gt; [1] "Mol. Cancer Ther."
#&gt; 
#&gt; $content$records[[9]]$source$full_journal_title
#&gt; [1] "Molecular cancer therapeutics"
#&gt; 
#&gt; $content$records[[9]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[9]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[9]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[9]]$variant_id
#&gt; [1] 93
#&gt; 
#&gt; $content$records[[9]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[10]]
#&gt; $content$records[[10]]$id
#&gt; [1] 22
#&gt; 
#&gt; $content$records[[10]]$name
#&gt; [1] "EID22"
#&gt; 
#&gt; $content$records[[10]]$description
#&gt; [1] "In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months."
#&gt; 
#&gt; $content$records[[10]]$disease
#&gt; $content$records[[10]]$disease$id
#&gt; [1] 7
#&gt; 
#&gt; $content$records[[10]]$disease$name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[10]]$disease$display_name
#&gt; [1] "Melanoma"
#&gt; 
#&gt; $content$records[[10]]$disease$doid
#&gt; [1] "1909"
#&gt; 
#&gt; $content$records[[10]]$disease$url
#&gt; [1] "http://www.disease-ontology.org/?id=DOID:1909"
#&gt; 
#&gt; 
#&gt; $content$records[[10]]$drugs
#&gt; $content$records[[10]]$drugs[[1]]
#&gt; $content$records[[10]]$drugs[[1]]$id
#&gt; [1] 11
#&gt; 
#&gt; $content$records[[10]]$drugs[[1]]$name
#&gt; [1] "Temozolomide"
#&gt; 
#&gt; $content$records[[10]]$drugs[[1]]$pubchem_id
#&gt; [1] ""
#&gt; 
#&gt; 
#&gt; 
#&gt; $content$records[[10]]$rating
#&gt; [1] 2
#&gt; 
#&gt; $content$records[[10]]$evidence_level
#&gt; [1] "C"
#&gt; 
#&gt; $content$records[[10]]$evidence_type
#&gt; [1] "Predictive"
#&gt; 
#&gt; $content$records[[10]]$clinical_significance
#&gt; [1] "Sensitivity/Response"
#&gt; 
#&gt; $content$records[[10]]$evidence_direction
#&gt; [1] "Supports"
#&gt; 
#&gt; $content$records[[10]]$variant_origin
#&gt; [1] "Somatic Mutation"
#&gt; 
#&gt; $content$records[[10]]$drug_interaction_type
#&gt; NULL
#&gt; 
#&gt; $content$records[[10]]$status
#&gt; [1] "accepted"
#&gt; 
#&gt; $content$records[[10]]$open_change_count
#&gt; [1] 0
#&gt; 
#&gt; $content$records[[10]]$type
#&gt; [1] "evidence"
#&gt; 
#&gt; $content$records[[10]]$source
#&gt; $content$records[[10]]$source$id
#&gt; [1] 67
#&gt; 
#&gt; $content$records[[10]]$source$name
#&gt; [1] "NRAS-mutant melanoma: response to chemotherapy."
#&gt; 
#&gt; $content$records[[10]]$source$citation
#&gt; [1] "Soon et al., 2011, Arch Dermatol"
#&gt; 
#&gt; $content$records[[10]]$source$citation_id
#&gt; [1] "21576590"
#&gt; 
#&gt; $content$records[[10]]$source$source_type
#&gt; [1] "PubMed"
#&gt; 
#&gt; $content$records[[10]]$source$asco_abstract_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[10]]$source$source_url
#&gt; [1] "http://www.ncbi.nlm.nih.gov/pubmed/21576590"
#&gt; 
#&gt; $content$records[[10]]$source$open_access
#&gt; NULL
#&gt; 
#&gt; $content$records[[10]]$source$pmc_id
#&gt; NULL
#&gt; 
#&gt; $content$records[[10]]$source$publication_date
#&gt; $content$records[[10]]$source$publication_date$year
#&gt; [1] 2011
#&gt; 
#&gt; $content$records[[10]]$source$publication_date$month
#&gt; [1] 5
#&gt; 
#&gt; 
#&gt; $content$records[[10]]$source$journal
#&gt; [1] "Arch Dermatol"
#&gt; 
#&gt; $content$records[[10]]$source$full_journal_title
#&gt; [1] "Archives of dermatology"
#&gt; 
#&gt; $content$records[[10]]$source$status
#&gt; [1] "fully curated"
#&gt; 
#&gt; $content$records[[10]]$source$is_review
#&gt; [1] FALSE
#&gt; 
#&gt; $content$records[[10]]$source$clinical_trials
#&gt; list()
#&gt; 
#&gt; 
#&gt; $content$records[[10]]$variant_id
#&gt; [1] 95
#&gt; 
#&gt; $content$records[[10]]$phenotypes
#&gt; list()
#&gt; 
#&gt; 
#&gt; 
#&gt; 
#&gt; $url
#&gt; [1] "https://civicdb.org/api/evidence_items"
#&gt; 
#&gt; $response
#&gt; Response [https://civicdb.org/api/evidence_items?page=2&amp;count=10]
#&gt;   Date: 2019-09-03 16:44
#&gt;   Status: 200
#&gt;   Content-Type: application/json; charset=utf-8
#&gt;   Size: 12.6 kB
#&gt; 
#&gt; 
#&gt; attr(,"class")
#&gt; [1] "civic_api"</div></pre>
  </div>
  <div class="col-md-3 hidden-xs hidden-sm" id="sidebar">
    <h2>Contents</h2>
    <ul class="nav nav-pills nav-stacked">
      <li><a href="#arguments">Arguments</a></li>
      
      <li><a href="#value">Value</a></li>
      
      <li><a href="#examples">Examples</a></li>
    </ul>

  </div>
</div>

      <footer>
      <div class="copyright">
  <p>Developed by Andrew Duncan.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="https://pkgdown.r-lib.org/">pkgdown</a> 1.3.0.</p>
</div>
      </footer>
   </div>

  

  </body>
</html>

